Pharma Q4 outlook mixed with steady hospitals and generics pressure
Pharmaceuticals sector outlook for Q4 is mixed, with hospitals showing steady growth while generics face challenges from Revlimid sales decline. Lupin and Divi's are expected to perform well, while Sun Pharma benefits from strong domestic and international momentum.
pre-market1 source ↓written by the desknot a recommendation
The pharmaceuticals sector is facing a mixed outlook for Q4. Hospital chains are expected to show steady growth, while generic drugmakers are pressured by the absence of Revlimid sales. Lupin is projected to report strong growth in revenue and profit, while Divi's may benefit from improving contract development demand. Sun Pharma and Torrent are expected to maintain steady growth due to their diversified portfolios.
Not investment advice. For informational purposes only.